ROBIN SHERRINGTON has filed 10 insider transactions across 1 company since December 2023.
Most recent transaction: a grant/award of 65000 shares of Xenon Pharmaceuticals Inc. ($XENE) on March 11, 2024.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | A | Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 66,889,005 | 9999.99% | 0.10% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | M | Common Shares | 1234 | $9.85 | 9,632.0000 | 66,889,005 | 14.69% | 0.00% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | F | Common Shares | 215 | $45.96 | 9,417.0000 | 66,889,005 | 2.23% | 0.00% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | M | Common Shares | 7407 | $9.85 | 16,824.0000 | 66,889,005 | 78.66% | 0.01% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | F | Common Shares | 1289 | $45.96 | 15,535.0000 | 66,889,005 | 7.66% | 0.00% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | S | Common Shares | 1019 | $46.15 | 14,516.0000 | 66,889,005 | 6.56% | 0.00% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | S | Common Shares | 6118 | $46.30 | 8,398.0000 | 66,889,005 | 42.15% | 0.01% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | M | Stock Option (Right to Buy) | 1234 | $0.00 | 0.0000 | 66,889,005 | 100.00% | 0.00% |
| March 7, 2024 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | M | Stock Option (Right to Buy) | 7407 | $0.00 | 0.0000 | 66,889,005 | 100.00% | 0.01% |
| Dec. 29, 2023 | Xenon Pharmaceuticals Inc. | $XENE | ROBIN SHERRINGTON | EVP, Strategy & Innovation | J | Common Shares | 8398 | $0.00 | 8,398.0000 | 60,542,142 | 50.00% | 0.01% |